Trial
NCT04335721
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Illinois at Chicago
Collaborators
Global Blood Therapeutics
Condition
Sickle Cell Disease
Intervention
Voxelotor
Why stopped
Sponsor voluntarily suspended distribution and removed product from the market
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-03